ABSTRACT Boron- B concentrations that cause deficiency and those that cause toxicity appear to be very similar, compared to other nutrients, which can complicate successful management of this element in soils. In this study, B adsorption onto two Oxisols from Brazil (Rhodic Eutroperox and Anionic Acroperox), two Alfisols (Natric Palexeralf and Aridic Paleustalf) and an Entisol (Xeric Torrifluvent) from the United States of America were evaluated. The samples were treated with sodium hypochlorite in order to remove soil organic matter. Both treated and untreated samples were used to determine B adsorption isotherms using different B concentrations (0-4.630 mmol L–1) and NaNO3 (0.05 M) as background electrolyte solution at pH 7. Boron adsorption envelopes were also measured using 0.463 mmol L–1 B at three ionic strengths (0.05, 0.1 and 1M) and NaNO3 as background electrolyte solutions at different pH values (3-12). The cation exchange capacity, specific surface area, free Al and Fe oxides, organic and inorganic carbon content, mineralogy and particle size distribution of the soils were also determined. The Langmuir isotherm and the constant capacitance model were fit to the B adsorption data and the parameters obtained were related to the chemical attributes by multiple linear regression equations. Boron maximum adsorption capacity (BMAC) and the complexation constant for the SH3BO4– inner-sphere complex (LogKB–) could be predicted under all experimental conditions. The Alc content was the main soil chemical attribute associated with the BMAC under the conditions evaluated and the LogKB–(int) in untreated and treated samples.

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. The disease has a highly variable clinical course, ranging from very indolent cases to patients with aggressive and rapidly progressing outcome. Genetic studies are useful tools in the analysis of this pathology, and are incorporated in international risk classifications. The analysis of genomic rearrangements and the mutational status of immunoglobulin heavy chain variable have allowed risk groups of high prognostic value to be established. More recently, next generation sequencing studies have identified novel somatic mutations that could explain the wide clinical variability of this pathology. Among them, the analysis of NOTCH1 (neurogenic locus notch homolog protein 1) gene mutations are of interest, as deregulation is associated with tumorigenesis. NOTCH1 mutations are mostly located at exon 34 (80% of cases) and 3´UTR (untranslated region). They produce premature stop codons that produce a constitutively active and stable NOTCH1 protein. NOTCH1 mutations are associated with adverse prognosis and refractoriness to treatment. The aim of this study was to analyze NOTCH1 mutations in CLL patients by ASO-PCR and sequencing. Our results found 4.4% of cases with NOTCH1 mutated values concordant with international observations (5%-10%). Including them in the genetic status of CLL patients allows the characterization of risk groups, an aspect of great importance in clinical practice and therapeutic decisions, to be refined.

La leucemia linfocítica crónica (LLC) es la leucemia más frecuente en adultos de Occidente. Presenta un curso clínico altamente variable, con pacientes que requieren tratamiento inmediato y otros con un curso indolente de la enfermedad. Los estudios genéticos constituyen herramientas de suma utilidad en esta enfermedad, encontrándose incorporados a las clasificaciones de riesgo internacionales. El análisis de los rearreglos genómicos y del estado mutacional de los genes IGHV (immunoglobulin heavy chain variable region) ha hecho factible establecer grupos de riesgo de alto valor pronóstico. Más recientemente, estudios de secuenciación de última generación permitieron la detección de mutaciones somáticas previamente desconocidas en esta afección, que podrían explicar la amplia variabilidad clínica observada en la LLC. Entre ellas, resultan de interés las observadas en el gen NOTCH1 (neurogenic locus notch homolog protein 1), cuya desregulación se asocia con el desarrollo tumoral. Estas mutaciones se acumulan en mayor medida en el exón 34 (80% de los casos) y en la región 3´UTR (untraslated region), lo que genera codones de terminación prematuros que originan una proteína NOTCH1 constitutivamente activa y más estable, los cuales se asocian con pronóstico adverso y refractariedad al tratamiento. Nuestro objetivo fue evaluar mutaciones de NOTCH1 en nuestros pacientes mediante ASO-PCR y secuenciación. Se detectaron mutaciones en el 4.4% de los casos, valor concordante con los datos internacionales (5% a 10%). Su inclusión en la caracterización genética de los pacientes con LLC permitirá refinar la categorización de los grupos de riesgo, aspecto de suma importancia tanto en el seguimiento clínico como en la toma de decisiones terapéuticas.